Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-S1 in Adult Patients with COVID-19
NCT05822180Phase 3Completed
- Sponsor
- General Administration of Military Health
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Nano-S1 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by General Administration of Military Health. Primary endpoint: Clinical evolution at 14 days. Started Jan 2021; status: completed.
02
Drugs
Nano-S1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05822180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822180.